Travere Therapeutics Inc. (TVTX)
NASDAQ · Healthcare
Travere Therapeutics Inc. Shareholder Equity 2011–2025
Travere Therapeutics Inc. annual shareholder equity history from 2012 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Travere Therapeutics Inc. shareholder equity as of December 31, 2025: 114.8M, a 94.37% increase year-over-year.
- Travere Therapeutics Inc. shareholder equity for 2025 were 114.8M, a 94.37% increase from 2024.
- Travere Therapeutics Inc. shareholder equity for 2024 were 59.1M, a 70.58% decrease from 2023.
- Travere Therapeutics Inc. shareholder equity for 2023 were 200.8M, a 368.62% increase from 2022.
- Travere Therapeutics Inc. shareholder equity for 2022 were 42.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Travere Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $115 |
| 2024 | $59 |
| 2023 | $201 |
| 2022 | $43 |
| 2021 | $302 |
| 2020 | $211 |
| 2019 | $221 |
| 2018 | $318 |
| 2017 | $293 |
| 2016 | $308 |
| 2012 | $-0 |
Travere Therapeutics Inc. Shareholder Equity — FAQ
Travere Therapeutics Inc. (TVTX) shareholder equity over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TVTX's shareholder equity history?
The chart and table above show Travere Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.